Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06512454

A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems

The liver produces a protein called alpha-1 antitrypsin (AAT). AAT is normally released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells and also leads to low blood levels of AAT (called Alpha-1 Antitrypsin Deficiency or AATD). Over time, this build up leads to different stages of liver problems, if not treated. This is called natural history of AATD.

The main aim of this study is to learn about liver problems caused by AATD in adults when not treated over 4 to 8 years. Other aims are to learn what can predict the AATD-liver condition starting and getting better or worse, describe how this condition is currently being diagnosed and watched in normal care, and describe how the AATD also affects an adult's lung function.

Data in this study will be collected to include medical history of a participant, including the date AATD was first identified and/or the date on which the first AATD-related liver or lung problems were diagnosed. At study start and then every year until study end, participants will be asked to complete questionnaires (called patient-reported outcomes or PROs).

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Alpha1-Antitrypsin Deficiency Congenital, Hereditary, and Neonatal Diseases and Abnormalities Digestive System Diseases Emphysema Genetic Diseases, Inborn Liver Diseases Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Respiratory Tract Diseases Subcutaneous Emphysema alpha 1-Antitrypsin Deficiency

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Vienna General Hospital (AKH Wien), Vienna, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Participants who meet all the following criteria will be included in the study.

Cohorts 1 and 2:

  • Willing to provide written informed consent to participate in the study.
  • >=18 years of age at enrollment in this study.
  • Participants with documented diagnosis of AATD, meeting the following criteria:
  • Cohort 1 (AATD-Pi*ZZ genotype/phenotype).
  • Pi*ZZ genotype as documented from rapid genetic assay, sequencing, or polymerase chain reaction (PCR), or Pi*ZZ phenotype as documented from iso-electric focusing (IEF) electrophoresis.
  • Cohort 2 (AATD-Pi*SZ genotype/phenotype with liver disease manifestation).
  • Pi*SZ genotype as documented from rapid genetic assay, sequencing, or PCR, or Pi*SZ phenotype as documented from IEF electrophoresis, and
  • Moderate-advanced or severe liver disease manifestation as defined by either liver biopsy or surrogate laboratory or imaging measures.

Exclusion criteria

Participants who meet any following criteria will be excluded from the study.

  • Documented AATD genotype/phenotype other than Pi*ZZ or Pi*SZ.
  • History of liver transplant.
  • No results for either biopsies, magnetic resonance elastography (MRE), FibroScan (vibration controlled transient elastography [VCTE]), or Aspartate aminotransferase to platelet ratio index (APRI) in the 24 months prior to the index/enrollment date and has none of these tests ordered during the index period (i.e., index date +90 days).
  • Participants with prior participation in an interventional clinical trial evaluating liver or lung disease, or who have received an investigational AATD-directed therapy under a compassionate use program, will be excluded if they do not present one of the following:
  • A minimum washout period of 6 months has elapsed since the last dose of the investigational product.
  • A history of having received placebo in prior interventional trials (to be evaluated on a case-by-case basis).

Treatment and study plan

No intervention

Other

This is an observational study.

Primary outcomes

  1. Number of Participants With Liver Disease Progression

    Time frame: Baseline up to 8 years

    Liver disease progression will be defined as advancement in greater than or equal to (>=)1 fibrosis stage: example any progression from fibrosis stage F0/F1 to F2, F1 to F2, F2 to F3 etc. and/or occurrence of any of these composite events: a) advancement in >=1 fibrosis stage, b) development of a liver disease-related clinical event, c) model for end-stage liver disease (MELD) score increase, d) newly added on liver transplant list, e) receipt of a liver transplant. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis. The MELD score ranges from 6 to 40 with higher scores indicating more severe liver disease and a worse outcome.

  2. Time to Liver Disease Progression

    Time frame: Baseline up to 8 years

    Time to liver disease progression is defined as time to advancement in >=1 fibrosis stage (example F0/F1 to F2, F2 to F3 etc.) and/or time to the earliest of: Advancement in >=1 fibrosis stage, or development of a liver disease-related clinical event, or MELD score increase or receipt/newly added to transplant list of a liver transplant. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis. The MELD score ranges from 6 to 40 with higher scores indicating more severe liver disease and a worse outcome.

  3. Time to Liver Disease Trajectory

    Time frame: Baseline up to 8 years

    Time to liver disease trajectory is defined as time of transition from F0/F1 to F2, F2 to F3, F3 to F4, F4 to the first decompensating event or liver transplant/listing and first to second decompensating event and all subsequent decompensating events or liver transplant/listing. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis.

  4. Probability of Transition in Liver Disease Trajectory

    Time frame: Baseline up to 8 years

    Probability of liver disease trajectory is defined as probability of transition from F0/F1 to F2, F2 to F3, F3 to F4, F4 to the first decompensating event or liver transplant/listing and first to second decompensating event and all subsequent decompensating events or liver transplant/listing. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis.

  5. Percentage of Participants With Disease Regression

    Time frame: Baseline up to 8 years

    Disease regression is defined as decrease in >=1 fibrosis staging. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis.

  6. Time to Liver Disease Regression

    Time frame: Baseline up to 8 years

    Time to liver disease regression is defined as time to decrease in >=1 fibrosis stage. The fibrosis stages range from F0 to F4, with F0 indicating no fibrosis and F4 indicating cirrhosis.

  7. Percentage of Participants With All-cause Mortality and Cause-specific Mortality

    Time frame: Baseline up to 8 years

    Cause-specific mortality is defined as mortality due to liver failure or complications of cirrhosis/portal hypertension or hepatocellular carcinoma, or infections secondary to liver failure.

  8. Time to Death (All-causes) and Cause-specific Death (Liver Disease-specific Causes)

    Time frame: Baseline up to 8 years

    Cause-specific mortality is defined as mortality due to liver failure or complications of cirrhosis/portal hypertension or hepatocellular carcinoma, or infections secondary to liver failure.

Secondary outcomes

  1. Percentage of Participants Who Develop Lung Disease

    Time frame: Baseline up to 8 years

    Development of lung disease will be defined as either a forced expiratory volume in 1 second (FEV1) percent (%) predicted of less than (<) 70% or the diagnosis of at least 1 lung condition (chronic obstructive pulmonary disease [COPD], emphysema, bronchiectasis, chronic bronchitis) over the study duration or at specific timepoints.

  2. Proportion of Participants With Lung Disease at Baseline who Experience Lung Disease Progression at 4-8 Years

    Time frame: Baseline up to 8 years

    Lung disease progression is defined as changes in pulmonary function (defined as >=10% absolute change in FEV1, forced vital capacity [FVC], or diffusing capacity of the lungs for carbon monoxide [DLCO]) over the study duration or at specific timepoints.

  3. Characterize Diagnostic and Monitoring Patterns for Liver Disease (Invasive and Non-invasive Assessments)

    Time frame: Baseline up to 8 years

Study contacts

Contact information is provided by the study sponsor or research team.

Takeda Contact

CONTACT

[email protected]

+1-877-825-3327

Sponsors and collaborators

Lead sponsor

Takeda

Industry

Registry information

Official study title

Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency and Associated Liver Disease

Acronym: ALPHATUDE

Important dates

Study start
2024
Primary completion
2031
Study completion
2031
First posted
Jul 22, 2024
Registry last updated
Jul 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.